3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 2: Optimization of the side chains to improve in vitro and in vivo potencies

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 4, 2010, Pages 1641-1658

  Asada, Masaki ^a   Iwahashi, Maki ^a   Obitsu, Tetsuo ^a   Kinoshita, Atsushi ^a   Nakai, Yoshihiko ^a   Onoda, Takahiro ^a   Nagase, Toshihiko ^a   Tanaka, Motoyuki ^a   Yamaura, Yoshiyuki ^a   Takizawa, Hiroya ^a   Yoshikawa, Ken ^a   Sato, Kazutoyo ^a   Narita, Masami ^a   Ohuchida, Shuichi ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Antagonist; EP3 receptor; Uterine contraction

Indexed keywords

3 [2 [[[1 (2 FLUOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (2 METHOXYPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (2,3 DIHYDRO 1,4 BENZODIOXIN 6 YL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3 CHLORO 4 FLUOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3 CHLOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3 FLUORO 4 METHOXYPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3 FLUORO 4 METHYLPHENYL) 3 METHYLBUTYL] AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3 FLUOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3 METHOXYPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3,4 DIFLUOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3,4 DIMETHOXYPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3,4 DIMETHYLPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3,5 DIFLUOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3,5 DIMETHYLPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (3,5 DIMETHYLPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 [(2-FLUOROPHENOXY)METHYL]PHENYL]PROPANOIC ACID; 3 [2 [[[1 (4 CHLOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (4 FLUORO 3 METHYLPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (4 FLUOROPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (4 METHOXY 3 METHYLPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 (4 METHOXYPHENYL) 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 [3 FLUORO 4 (TRIFLUOROMETHYL)PHENYL] 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 3 METHYLBUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[3 METHYL 1 (2 METHYLPHENYL)BUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[3 METHYL 1 (3 METHYLPHENYL)BUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[3 METHYL 1 (4 METHYLPHENYL)BUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[3 METHYL 1 [3 (TRIFLUOROMETHYL)PHENYL]BUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; 3 [2 [[[3 METHYL 1 [4 (TRIFLUOROMETHYL)PHENYL]BUTYL]AMINO]CARBONYL] 4 (PHENOXYMETHYL)PHENYL]PROPANOIC ACID; PROPIONIC ACID DERIVATIVE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; UTERUS CONTRACTION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PREGNANCY; PROPIONIC ACIDS; RATS; RECEPTORS, PROSTAGLANDIN E; UTERINE CONTRACTION;

RATTUS;

EID: 75849153508     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.12.068     Document Type: Article

References (16)

1. Coleman R.A., Grix S.P., Head S.A., Louttit J.B., Mallett A., and Sheldrick R.L.G. Prostaglandins 47 (1994) 151
2. Negishi M., Sugimoto Y., and Ichikawa A.J. Lipid Mediat. Cell Signal. 12 (1995) 379
3. Sorbera L.A., Bozzo J., Rosa E., and Dulsat C. Drugs Future 33 (2008) 455
4. Breyer M.D., Hebert R.L., and Breyer R.M. Curr. Opin. Invest. Drugs 4 (2003) 1343
5. Cameron K.O., Lefker B.A., Ke H.Z., Li M., Zawistoski M.P., Tjoa C.M., Wright A.S., DeNinno S.L., Paralkar V.M., Owen T.A., Yu L., and Thompson D.D. Bioorg. Med. Chem. Lett. 19 (2009) 2075
6. Singh J., Zeller W., Zhou N., Hategen G., Mishra R., Polozov A., Yu P., Onua E., Zhang J., Zembower D., Kiselyov A., Ramirez J.L., Sigthorsson G., Bjornsson J.M., Thorsteinsdottir M., Andresson T., Bjarnadottir M., Magnusson O., Fabre J.E., Stefansson K., and Gurney M.E. ACS Chem. Biol. 4 (2009) 115
7. Ohta C., Kuwabe S., Shiraishi T., Shinohara I., Araki H., Sakuyama S., Makihara T., Kawanaka Y., Ohuchida S., and Seko T. J. Org. Chem. 74 (2009) 8298
8. RaQualia Phrma Inc. Home Page. http://www.raqualia.co.jp/.
9. Just S., Arndt K., Weiser T., and Doods H. Drug Discovery Today Dis. Mech. 3 (2006) 327
10. Asada M., Obitsu T., Nagase T., Tanaka M., Yamaura Y., Takizawa H., Yoshikawa K., Sato K., Narita M., Ohuchida S., Nakai H., and Toda M. Bioorg. Med. Chem. 18 (2010) 80
11. Backes B.J., Dragoli D.R., and Ellman J.A. J. Org. Chem. 64 (1999) 5472
12. Rodriques K.E., Basha A., Summers J.B., and Broocks D.W. Tetrahedron Lett. 29 (1988) 3455
13. Satoh T., Nanba K., and Suzuki S. Chem. Pharm. Bull. 19 (1971) 817
14. Cohen B.J., Karoly-Hafeli H., and Patchornik A. J. Org. Chem. 49 (1984) 922
15. Senior J., Marshall K., Sangha R., Baxter G.S., and Clayton J.K. Br. J. Pharmacol. 102 (1991) 747
16. Goureau O., Tanfin Z., Marc S., and Harbon S. Am. J. Physiol. 263 (1992) C257